Voluntary Health Industry Deals on Drug Prices, Food Dyes, and Prior Authorization Lack Enforcement and Fall Short of Promises
核心洞察
Several high-profile federal health initiatives rely on voluntary industry agreements rather than regulation, and reporting finds the promised changes have largely not arrived on the announced timelines.
The FDA quietly moved its synthetic dye removal deadline from the end of 2026 to the end of 2027, with fewer than 30% of pledged companies meeting their goals.
Health plans reduced prior authorization for medical services by only about 11% as of July, far short of the announced January 2026 target, and promised public dashboards have not launched.
Several of the highest-profile federal health announcements of the past two years rest on voluntary industry agreements rather than regulation, and reporting published this week finds that the promised changes have largely not arrived on the timelines announced. Each agreement was presented as a consumer benefit — fewer synthetic dyes in food, lower drug prices, and fewer insurance preapproval requirements standing between a patient and a treatment — yet voluntary commitments carry no enforcement mechanism, no penalty for missing a deadline, and in these cases limited public documentation.
"These deals are often not transparent, so there's no way for the public to judge," said Larry Levitt, executive vice president for health policy at KFF, describing how hard it is to assess whether the agreements are meaningful.
The Food Dye Deadline Moved Quietly
In April 2025, federal health officials announced that food companies would voluntarily stop using six specific synthetic dyes by the end of 2026, part of a stated push targeting nine synthetic dyes overall. Authorization for two others has been revoked or proposed for revocation.
The FDA later changed the deadline on its website to the end of 2027. Most of the targeted dyes remain in use. The agency's tracking page listed 27 companies that had made voluntary pledges as of December 2025 to remove six synthetic dyes from products. According to KFF Health News, seven of those companies — fewer than 30 percent — had met their stated goals more than a year and a half later. Consumer Reports found that major food makers including Coca-Cola and Unilever have made no concrete commitments, and no pharmaceutical company has publicly announced plans to remove dyes from medications.
Labeling rules also loosened. Companies may now claim a product contains no artificial colors as long as it does not use petroleum-based dyes. Previously, that claim required no added colors at all. Some naturally derived colorings can carry their own contaminants and health questions.
"The federal government hasn't taken any regulatory action on food dyes," said Melanie Benesh, vice president for government affairs at the Environmental Working Group, describing the period since the start of this administration.
HHS disputes the characterization. "HHS and the FDA are moving forward with clear timelines and concrete industry commitments," HHS spokesperson Emily Hilliard said, pointing to changes expected in foods served in schools this year and across full product portfolios by the end of 2027.
Public interest is not in question. In a nationally representative Consumer Reports survey in March, 72 percent of adults said they were at least somewhat concerned about synthetic dyes, and two-thirds said companies should be required to phase them out.
Prior Authorization Reform Fell Short of Its Own Target
In June 2025, HHS and the Centers for Medicare and Medicaid Services announced that major insurers had agreed to reduce the volume of services requiring prior authorization. The administration said 80 percent of insurers had pledged changes covering 80 percent of diseases and injuries by January 2026, and promised public dashboards to track progress.
As of July, months past that target, health plans had reduced prior authorization for medical services by about 11 percent, according to AHIP, the insurer trade group. No public dashboards have launched. Some insurers that signed the pledge have said they will not implement all the promised reforms.
Insurers made a similar pledge in 2018. The following year, more than 80 percent of physicians surveyed by the American Medical Association reported that prior authorization requests had been increasing. In a 2025 survey of 1,000 practicing physicians by the American Medical Association, only one in three believed the voluntary pledges would make a meaningful difference.
Meanwhile, a separate program using artificial intelligence to screen prior authorization requests began in traditional Medicare in January in six states, covering a small number of treatments regulators consider low-benefit or prone to fraud and waste, including skin substitutes and knee arthroscopy for arthritis.
The Narrow Scope of the Drug Pricing Agreements
Seventeen drugmakers, including Pfizer and AstraZeneca, have announced agreements with the administration to lower prices for Medicaid enrollees and cash-paying consumers through a government-run consumer platform called TrumpRx, under a policy benchmarking US prices to those in peer countries. The White House calls it the "most-favored-nation" prescription drug pricing policy.
The scope is narrower than the announcements suggest. The lower prices apply to new drugs and to existing drugs available through Medicaid. Platform prices are not lower than typical out-of-pocket costs for most insured consumers, and the deals do not apply to existing drugs used by the more than 200 million Americans with commercial or private coverage.
Drugmaker share prices largely rose rather than fell after the announcements, which analysts attributed partly to the narrow scope of the agreements. "Each company makes its own decisions about how it prices medicines, and our industry is committed to working with the Trump administration to ensure Americans have access to affordable medicines," said Chanse Jones, a spokesperson for PhRMA (搜索), a pharmaceutical industry trade group.
Supporters argue speed is the point. Enacting a federal regulation typically takes two to three years, while an agreement can be announced in weeks. David Mansdoerfer, a political consultant and former HHS political appointee, defended the approach as favoring communication over coercion.
Critics note the historical record. After Congress rejected a legislative plan to curb hospital costs in the late 1970s, it favored a voluntary approach instead, which ultimately failed once public attention faded.
Steps Consumers Can Verify Themselves
None of this is a reason for anyone to change medications or coverage. It is a reason to check specifics rather than headlines. Shoppers who want to avoid synthetic dyes should read ingredient panels rather than front-of-package claims, since the labeling rule changed. Patients facing a prior authorization delay should ask the prescriber's office to request a peer-to-peer review, request the denial in writing, and file an appeal. Patients comparing drug prices should check the government platform price against a pharmacy discount card price and their own insurance copay, because the lowest of the three varies by drug.